血清转化生长因子-β1水平与胰腺癌风险：一项巢式病例对照研究（日本）

Serum transforming growth factor-beta1 levels and pancreatic cancer risk: a nested case-control study (Japan).

作者信息

Lin Yingsong, Kikuchi Shogo, Tamakoshi Akiko, Obata Yuki, Yagyu Kiyoko, Inaba Yutaka, Kurosawa Michiko, Kawamura Takashi, Motohashi Yutaka, Ishibashi Teruo

机构信息

Department of Public Health, Aichi Medical University School of Medicine, 21 Karimata, Yazako, Aichi-gun, Aichi, Japan.

出版信息

Cancer Causes Control. 2006 Oct;17(8):1077-82. doi: 10.1007/s10552-006-0048-0.

DOI:10.1007/s10552-006-0048-0

PMID:16933058

Abstract

OBJECTIVE

To examine the relationship of baseline levels of serum TGF-beta1 to the subsequent risk of death from pancreatic cancer in a nested case-control study.

METHODS

The cases were 85 persons who had provided a blood sample at baseline and subsequently died of pancreatic cancer during the study period. For each case, three controls were randomly selected from among the cohort participants, and were matched for each case by sex, age (+/-1 year), and study area. Serum TGF-beta1 levels were measured with enzyme-linked immunosorbent assay (ELISA). Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated from conditional logistic models.

RESULTS

The mean of serum TGF-beta1 levels was significantly higher among cases than among controls (p = 0.01). Individuals with serum TGF-beta1 levels in the highest quartile had a 2.5-fold increase in risk as compared with those in the lowest quartile (OR, 2.5; 95% CI, 0.9-6.9), after adjustment for month of blood draw, cigarette smoking, body mass index and history of diabetes. Excluding 12 pancreatic cancer deaths that occurred within three years of follow-up did not alter the positive association.

CONCLUSION

Our prospective data indicate that high serum TGF-beta1 levels may be associated with an increased risk of death from pancreatic cancer.

摘要

目的

在一项巢式病例对照研究中，探讨血清转化生长因子β1（TGF-β1）基线水平与后续胰腺癌死亡风险之间的关系。

方法

病例为85名在基线时提供了血样且在研究期间死于胰腺癌的患者。对于每例病例，从队列参与者中随机选取3名对照，并按性别、年龄（±1岁）和研究区域与每例病例进行匹配。采用酶联免疫吸附测定（ELISA）法检测血清TGF-β1水平。根据条件逻辑模型计算比值比（OR）和95%置信区间（CI）。

结果

病例组血清TGF-β1水平均值显著高于对照组（p = 0.01）。在对采血月份、吸烟、体重指数和糖尿病史进行校正后，血清TGF-β1水平处于最高四分位数的个体与最低四分位数的个体相比，风险增加了2.5倍（OR，2.5；95%CI，0.9 - 6.9）。排除随访3年内发生的12例胰腺癌死亡病例后，这种正相关关系并未改变。